Topic:

R&D

Latest Headlines

Latest Headlines

Biogen Idec inks $30M genetic R&D alliance with Columbia University

Some of the cash will go toward creating a sequencing and analysis center at Columbia to support collaborative research.

Incyte, Agenus partner on immuno-oncology targets in $410M deal

Incyte is jumping aboard Agenus' antibody discovery platform, signing up to partner on new immuno-oncology drugs with $60 million in cash and promises of up to $350 million in milestones. And the deal news quickly drove up Agenus' shares by more than 30% in premarket trading.

Pfizer nears a new dawn in oncology with AstraZeneca in the rearview

Pfizer appears to be speeding toward a crucial early FDA approval for palbociclib, a breast cancer treatment with blockbuster potential, pivoting from its failed bid for AstraZeneca and building up an oncology pipeline of its own.

UPDATED: Biogen Idec's remyelination drug raises hopes--and fears--in PhII

Shares of Biogen Idec were buoyed this morning after the big biotech highlighted positive data from its mid-stage study of anti-LINGO-1, a closely watched drug that raises the potential for spurring remyelination--repairing the damage done by diseases like multiple sclerosis. But a careful second look at the results also underscores just how challenging this development program is for Biogen Idec.

Isis launches a cardio subsidiary and recruits a Genzyme vet to run it

Isis Pharmaceuticals is shifting its cardiovascular pipeline into a new subsidiary, cutting the ribbon on Akcea Therapeutics and appointing former Genzyme executive Paula Soteropoulos to lead the way.

Australia's EnGeneIC receives $10M in Series B round for studies of anticancer delivery tech

Australia's EnGeneIC announced the completion of a $10 million Series B round for its antibody-targeted EDV nanocell technology platform for cancer drug delivery, led by Boston's GRT Capital Partners.

Graphene 'flying carpet' strips deliver two cancer drugs, each to a different cell target

Researchers have developed graphene strips that have demonstrated the ability to carry two different cancer drugs and target each to the part of the cell where it will be most effective. The surface area of a flat strip in particular suits these particles to the delivery of the cancer drugs TRAIL and doxorubicin.

Alkermes sees PhII promise for schizophrenia drug that doesn't pack on pounds

When Alkermes set out to develop ALKS 3831 for schizophrenia, it took a well-known antipsychotic--olanzapine--and combined it with a mu-opioid antagonist called samidorphan with an eye to controlling the disease without spurring the rapid weight gain that has bedeviled patients for years. Today, the company says it got the data it was looking for in Phase II and will now press ahead into a pivotal, late-stage program to see if they can replicate the results on a larger scale.

Blend banks $21M for its nano-assisted cancer drugs

Blend Therapeutics, a biotech with ties to MIT serial entrepreneur Robert Langer, has hauled in $21 million in new financing to flesh out a novel approach to cancer treatment.

Novartis adopts a CRISPR-Cas9 partner and jumps into the hot new R&D field

Just weeks after Novartis and Atlas Venture announced the launch of an upstart player in the fast-emerging field of CRISPR-Cas9 gene editing, the pharma giant has stepped back up to formally hammer out a partnership development deal and throw its enormous resources behind the biotech.